| Name | Title | Contact Details |
|---|
LFI specializes in the sale and service of contemporary furnishings to public, private, school, and academic libraries. By meeting the rapidly changing sociological and technological changes through design and product, LFI has become the Midwests leading library furnishing company.
True Lacrosse is a sports organization founded in 2008 by professional lacrosse players Jake Deane and Mike Gabel, based in Lombard, Illinois. The organization is dedicated to educating and developing young men and women in lacrosse, focusing on creating exceptional athletes while fostering confidence, integrity, and leadership skills. Operating in multiple U.S. states, including Illinois, Colorado, and Michigan, True Lacrosse serves youth players nationwide. The organization emphasizes four core pillars: Passion, Energy, Expertise, and Reps, which guide their training and player development approach. True Lacrosse offers comprehensive training programs that enhance lacrosse skills, game understanding, and athleticism. Their experienced coaching staff, comprised of former professional players, provides valuable insights and support to help players reach their potential and pursue collegiate opportunities. Additionally, True Lacrosse prioritizes player safety by partnering with platforms like HEADCHECK Health to manage concussion risks.
Sensiba LLP is a prominent accounting and business consulting firm based in Pleasanton, California. Recently rebranded from Sensiba San Filippo LLP, the company focuses on providing a wide range of services, including audit, tax, and accounting services, as well as business consulting and tax advisory services. With a revenue of $77.3 million and around 390 employees, Sensiba is committed to enhancing business performance for its diverse clientele. The firm has received several accolades, including recognition as a Top 100 Firm by Accounting Today and being named a Top Workplace in the USA. Sensiba is also a Certified B Corporation, reflecting its dedication to social and environmental responsibility. The company fosters a people-first culture that values empathy, diversity, and collaboration, ensuring a supportive environment for both employees and clients.
Unlocking Your Businesss Full Potential with AI At AI Nomics, were driven by the vision to revolutionize your business approach. Our mission is to empower you to take on your operations with AI by your side, helping you overcome challenges and achieve your goals faster than ever before. How We Transform Your Business: The AI Nomics Approach Were here to make sure you spend more time doing what you love and less time on the mundane. Our framework is designed for smooth AI integration to address your needs and accelerate your success: The 4 As of AI Integration: 1. Analyze: We identify areas where AI can have the greatest impact and help define your goals. 2. Automate: We pinpoint repetitive tasks suitable for automation to save you time. 3. Augment: We find opportunities where AI can enhance your efficiency in crucial tasks. 4. Activate: We seamlessly integrate and activate tailored AI solutions into your operations. The AI Business Suite: Tools Tailored for Transformation Our AI Business Suite offers a range of smart tools designed for seamless integration, allowing you to harness the full benefits of AI effortlessly: • CustomerCare AI: Transform your customer interactions with an AI that handles queries and personalizes responses around the clock. • SalesBooster: Equip your site with a virtual sales expert that turns visitors into sales, any time of day. • LeadNova: Enhance your outreach with AI that personalizes communication and efficiently converts prospects into loyal customers. Get Started Now on your AI transformation journey: Claim your free AI consultation in our bio!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.